Item 9B. OTHER INFORMATION

Insider Adoption or Termination of Trading Arrangements:

During the fiscal quarter ended December 31, 2023, none of the Company's directors or officers informed it of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:


Name and Title	Date Adopted	Character of Trading Agreement	Aggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading Agreement			Duration
Mark S. Schroeder	12/7/2023	Rule 10b5-1 Trading Arrangement	Up to	(17,044)	(1) (2)	12/6/2024 (3)
President, Diagnostics Laboratories and Chief Operations Officer
Amy B. Summy	12/7/2023	Rule 10b5-1 Trading Arrangement	Up to	(4,916)	(1) (2)	4/1/2024 (3)
Chief Marketing Officer

(1) The figure presented represents the shares to be sold on the vesting of equity awards before reduction for shares to be withheld for tax purposes.

(2) Mr. Schroeder’s plan provides for the exercise of vested stock options and the associated sale of up to 2,119 shares of the Company’s Common Stock.

(3) This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales on the respective order entry date or (b) the date listed in the table.

Previous: Item 9A. CONTROLS AND PROCEDURES · Next: Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS